$TWST

BLAKE KATRYN sold $275K of TWST

BLAKE KATRYN sold 2,240 shares of Twist Bioscience Corp (TWST) at $122.88 ($0.28M total) on 2026-08-12.

Original reporting
SEC EDGAR · BLAKE KATRYN
Published Aug 14, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

This is a disclosed insider sale by a director. Without accompanying company-specific news, it mainly informs sentiment and positioning rather than fundamentals.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no new business or financial catalyst in the text.

03

What to watch

No 10b5-1 plan is cited, but the article also lacks context on total holdings, prior sales cadence, and whether the sale was part of a broader personal liquidity need.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-08-14, covering a sale dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience director Blake Katryn filed a Form 4 selling 2,240 shares at $122.88 on 2026-08-12 for about $275.3K total.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The disclosure is a Form 4 insider transaction, not earnings, guidance, or a corporate event. The article provides sale size and price but no new operational or financial information.

Market effects

No clear sector read-through from a single director’s small open-market sale.

None.

None.

Counterpoint

The sale may be pre-planned for liquidity or diversification and does not necessarily signal reduced confidence, especially since the filing does not confirm motive.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Blake Katryn

    Director who sold 2,240 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.